Literature DB >> 12032849

A comprehensive catalog of CpG islands methylated in human lung adenocarcinomas for the identification of tumor suppressor genes.

Masahiko Shiraishi1, Azumi Sekiguchi, Michael J Terry, Adam J Oates, Yuji Miyamoto, Ying H Chuu, Miyo Munakata, Takao Sekiya.   

Abstract

CpG island methylation is an important mechanism in gene silencing and is a key epigenetic event in cancer development. As yet, the number and identities of the genes that are inactivated in cancer cells has not been determined. In order to address this issue, we have performed a comprehensive isolation of CpG islands that are methylated in human lung adenocarcinomas. We have isolated approximately 200 CpG islands that are methylated in tumor DNA including those of known tumor-associated genes such as the HOXA5 gene. As the library contains the CpG islands of a number of known tumor suppressor genes it is highly likely that additional, previously unidentified tumor suppressor genes, will be present. On average, 1-2% of CpG islands were methylated specifically in tumors although this figure differed greatly between patients. This study provides an important resource in the search for genes inactivated in tumors and for the investigation of epigenetic dysregulation of gene expression by CpG island methylation.

Entities:  

Mesh:

Year:  2002        PMID: 12032849     DOI: 10.1038/sj.onc.1205454

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  Identification of driver and passenger DNA methylation in cancer by epigenomic analysis.

Authors:  Satish Kalari; Gerd P Pfeifer
Journal:  Adv Genet       Date:  2010       Impact factor: 1.944

Review 2.  Methods in DNA methylation profiling.

Authors:  Tao Zuo; Benjamin Tycko; Ta-Ming Liu; Juey-Jen L Lin; Tim H-M Huang
Journal:  Epigenomics       Date:  2009-12       Impact factor: 4.778

3.  Epigenetic Silencing of ALDH1L1, a Metabolic Regulator of Cellular Proliferation, in Cancers.

Authors:  Natalia V Oleinik; Natalia I Krupenko; Sergey A Krupenko
Journal:  Genes Cancer       Date:  2011-02

Review 4.  DNA methylation patterns in lung carcinomas.

Authors:  Gerd P Pfeifer; Tibor A Rauch
Journal:  Semin Cancer Biol       Date:  2009-02-20       Impact factor: 15.707

5.  An AscI boundary library for the studies of genetic and epigenetic alterations in CpG islands.

Authors:  Zunyan Dai; Dieter Weichenhan; Yue-Zhong Wu; Julia L Hall; Laura J Rush; Laura T Smith; Aparna Raval; Li Yu; Daniela Kroll; Joerg Muehlisch; Michael C Frühwald; Pieter de Jong; Joe Catanese; Ramana V Davuluri; Dominic J Smiraglia; Christoph Plass
Journal:  Genome Res       Date:  2002-10       Impact factor: 9.043

6.  Pathological and Prognostic Indications of the mdig Gene in Human Lung Cancer.

Authors:  Junwei Shi; Chitra Thakur; Yuzu Zhao; Yongsen Li; Lishen Nie; Qian Zhang; Zhuoyue Bi; Yao Fu; Priya Wadgaonkar; Bandar Almutairy; Liping Xu; Wenxuan Zhang; Yiran Qiu; M'kya Rice; Hongjuan Cui; Fei Chen
Journal:  Cell Physiol Biochem       Date:  2021-01-11

7.  HOXA5 inhibits metastasis via regulating cytoskeletal remodelling and associates with prolonged survival in non-small-cell lung carcinoma.

Authors:  Chi-Chung Wang; Kang-Yi Su; Hsuan-Yu Chen; So-Yi Chang; Chi-Fan Shen; Chia-Hung Hsieh; Qi-Sheng Hong; Ching-Cheng Chiang; Gee-Chen Chang; Sung-Liang Yu; Jeremy J W Chen
Journal:  PLoS One       Date:  2015-04-14       Impact factor: 3.240

8.  Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma.

Authors:  Akira Ooki; Wikum Dinalankara; Luigi Marchionni; Jun-Chieh J Tsay; Chandra Goparaju; Zahra Maleki; William N Rom; Harvey I Pass; Mohammad O Hoque
Journal:  Oncogene       Date:  2018-07-06       Impact factor: 9.867

9.  Intergenic, gene terminal, and intragenic CpG islands in the human genome.

Authors:  Yulia A Medvedeva; Marina V Fridman; Nina J Oparina; Dmitry B Malko; Ekaterina O Ermakova; Ivan V Kulakovskiy; Andreas Heinzel; Vsevolod J Makeev
Journal:  BMC Genomics       Date:  2010-01-19       Impact factor: 3.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.